Eric Lefkofsky Is Leveraging Powerful New Technologies To Innovate Within the Medical System

Eric Lefkofsky has earned a name for himself as a disrupter. His company, Tempus, was ranked in the top ten of CNBC’s Disruptor 50 list. This list consists of companies that are disrupting the face of their industries and changing things for the better. In the case of Tempus this means rethinking the nature of modern healthcare (Youtube).

One of the most impressive features boasted by Tempus medical research firm is a large scale and rapid genomic sequencing system. This successfully provides physicians with the ability to predict the most probable genetically influenced conditions. Currently, a physician using Tempus can see in advance which aspects of a patient’s lifestyle deserve extra attention. The end effect is areas of healthcare moving from a reactionary to a preventative outlook. Eric Lefkofsky has also proven that Tempus can be rapidly deployed for a wide variety of medical duties. 

COVID-19 gives one of the most important recent examples of the system’s flexibility. The company has been able to work through thousands of tests per day during the earliest part of the pandemic. And, Eric Lefkofsky points out, they’ve scaled up those numbers even more as time goes by. This has given doctors an impressive tool to help rapidly stratify patients based on risk factors and projected outcome. These examples make one thing abundantly clear. Eric Lefkofsky has created something truly amazing in Tempus. The company’s technologies can be leveraged to work with almost any medical condition that touches on genetic factors by using advanced AI. As the scope of both genomic and artificial intelligence research grows so will the potential applications for this innovative company. 

More on Eric Lefkofsky´s career and biography https://www.mcaad.org/explore/view/ep-11-impatient-with-tempusgroupons-eric-lefkofsky